Tomohiko Taniguchi

Tomohiko Taniguchi

Auto-generated profile, based on publicly available information

Tomohiko Taniguchi

Kobe City Medical Center General Hospital

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2020 in Circulation Journal
Verified
Journal Article
Open access
PDF file
YTYasuaki Takeji
Yasuaki Takeji
TTTomohiko Taniguchi
Tomohiko Taniguchi
TMTakeshi Morimoto
Takeshi Morimoto
NSNaritatsu Saito
Naritatsu Saito
KAKenji Ando
Kenji Ando
OIon behalf of the CURRENT AS Registry Investigators and K-TAVI Registry Investigators
on behalf of the CURRENT AS Registry Investigators and K-TAVI Registry Investigators
Background:There are no data comparing transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) outcomes in real clinical practice in Japan. Methods and Results:We combined 2 independent registries, the K-TAVI Registry (a 6-center prospective registry of consecutive patients who underwent TAVI) and the CURRENT AS Registry (a large, 27-center registry of 3,815 consecutive patients with severe aortic stenosis [AS]). In the K-TAVI Registry, 338 patients underwent TAVI with SAPIEN XT balloon-expandable valves from October 2013 to January 2016, whereas in the CURRENT AS Registry 237 patients with severe AS underwent SAVR from January 2003 to December 2011. Propensity score matching was conducted, with final cohort comprising 306 patients. The cumulative 2-year incidence of all-cause death and heart failure (HF) hospitalization did not differ significantly between the TAVI and SAVR groups (13.7% vs. 12.4% [P=0.81] and 7.9% vs 3.9% [P=0.13], respectively). After adjusting for residual confounders, there were no significant differences between the TAVI and SAVR groups in the risk for all-cause death (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.35–1.58; P=0.43) or HF hospitalization (HR 1.27; 95% CI 0.40–4.59; P=0.69). Conclusions:These findings from 2 independent Japanese registries suggest that the 2-year risk of all-cause mortality and HF does not differ significantly between TAVI and SAVR groups in real-world practice in Japan.

29 February 2020 in Heart
Verified
Journal Article
Closed access
PDF file
TTTomohiko Taniguchi
Tomohiko Taniguchi
TMTakeshi Morimoto
Takeshi Morimoto
YTYasuaki Takeji
Yasuaki Takeji
TKTakao Kato
Takao Kato
TKTakeshi Kimura
Takeshi Kimura
Contemporary Outcomes after Surgery and Medical Treatment in Patients with Severe Aortic Stenosis (CURRENT AS) registry was a large Japanese multicentre retrospective registry of consecutive patients with severe aortic stenosis (AS) before introduction of transcatheter aortic valve implantation. We sought to overview the data from the CURRENT AS registry to discuss the three major contemporary issues related to clinical practice in patients with severe AS: (1) under-referral/underuse of surgical aortic valve replacement (SAVR) in symptomatic patients with severe AS, (2) management of asymptomatic patients with severe AS and (3) management of patients with low-gradient severe aortic stenosis (LG-AS). First, despite the dismal prognosis of symptomatic patients with severe AS, SAVR, including those performed during follow-up, was reported to be underused. In the CURRENT AS registry, overall 53% of symptomatic patients underwent aortic valve replacement (AVR) during follow-up. Second, we reported that compared with conservative strategy, initial AVR strategy was associated with lower risk of all-cause death and heart failure hospitalisation in asymptomatic patients with severe AS. Although current recommendations for AVR are mainly dependent on the patient symptoms, some patients may not complain of any symptom because of their sedentary lifestyle. We also reported several important objective factors associated with worse clinical outcomes in asymptomatic patients with severe AS for risk stratification. Finally, initial AVR strategy was associated with better long-term clinical outcomes than conservative strategy in both patients with high-gradient AS and patients with LG-AS. The favourable effect of initial AVR strategy was also seen in patients with LG-AS with left ventricular ejection fraction of ≥50%.

1 May 2022 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
TTTomohiko Taniguchi
Tomohiko Taniguchi
SSShinichi Shirai
Shinichi Shirai
KAKenji Ando
Kenji Ando
YAYoshio Arai
Yoshio Arai
YSYoshiharu Soga
Yoshiharu Soga
KHKentaro Hayashida
Kentaro Hayashida

27 August 2025 in JACC: Advances
Verified
Journal Article
Open access
YTYasuaki Takeji
Yasuaki Takeji
TTTomohiko Taniguchi
Tomohiko Taniguchi
TMTakeshi Morimoto
Takeshi Morimoto
SSShinichi Shirai
Shinichi Shirai
TKTakeshi Kitai
Takeshi Kitai
CICURRENT AS registry-2 Investigators
CURRENT AS registry-2 Investigators
The prognostic impact of cardiac damage staging in severe aortic stenosis (AS) based on gradient patterns, symptoms, and initial treatment strategies is not well understood. This study aimed to assess the differences in characteristics and clinical outcomes of AS patients according to cardiac damage stage, stratified by gradient patterns, symptoms, and treatment strategies. A total of 3,369 consecutive patients with severe AS (high-gradient [HG] AS, n = 1986; low-gradient [LG] AS, n = 1,383) from the CURRENT AS registry-2 were included. Cardiac damage was categorized into 4 groups (stage 0, stage 1, stage 2, and stage 3/4). The cumulative incidence of the primary outcome (all-cause death or heart failure hospitalization) increased with advancing cardiac damage stages in both HG and LG AS. Adjusted HRs for stages 1, 2, and 3/4 vs stage 0 were significantly higher in both HG and LG cohorts (HG AS: HR: 2.47; 95% CI: 1.23-4.96 [stage 1]; HR: 3.39; 95% CI: 1.72-6.67 [stage 2]; HR: 4.01; 95% CI: 1.95-8.25 [stage 3/4]; LG AS: HR: 1.72; 95% CI: 1.04-2.84 [stage 1]; HR: 2.28; 95% CI: 1.44-3.61 [stage 2]; HR: 2.95; 95% CI: 1.79-4.88 [stage 3/4]). The higher risk of the primary outcome with more advanced cardiac damage was consistent regardless of the presence of symptoms and the initial treatment strategies in both HG and LG AS. Cardiac damage staging is a useful tool for prognostic stratification in patients with severe AS, independent of gradient patterns, symptoms, and initial treatment strategies.

26 April 2023 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
TTTomohiko Taniguchi
Tomohiko Taniguchi
YMYuta Matsui
Yuta Matsui
YFYutaka Furukawa
Yutaka Furukawa
A 57-year-old man with a history of human immunodeficiency virus infection presented with sudden pain and swelling of the right leg that had developed over the preceding thirty minutes (Panel A). He reported having been taking antiretroviral drugs. Computed tomography (CT) demonstrates partial pulmonary artery embolism and massive deep vein thrombosis extending from the right external iliac to the popliteal veins. Despite commencing anticoagulation, he had severe pain and intense dysesthesia of the right leg. The intramuscular pressure in his right leg was 98 mmHg (reference: <10 mmHg), and his right dorsalis pedis pulse was not palpable. A clinical diagnosis of compartment syndrome secondary to phlegmasia cerulea dolens was made, and he underwent immediate fasciotomy (Panel B). As the dysesthesias did not improve by fasciotomy, catheter-directed venous thrombectomy was performed on day 5 of hospitalization using a 10-French Heartrail ST01 catheter (Terumo, Tokyo, Japan) via a cross-over 12-French DrySeal (WL Gore, Flagstaff, Arizona, USA) from the contralateral femoral vein after placing an inferior vena cava (IVC) filter. Although the final venography revealed restored venous flow, the filter could not be retrieved because of trapped thrombi (Panel C-E, see supplementary data online, Videos S1–S3). Postprocedural CT demonstrated complete thrombosis of the right external iliac vein, and swelling in the right thigh was persistent despite anticoagulation and intermittent pneumatic compression. After the second venous thrombectomy on day 15, the venous flow was completely restored, and the filter was retrieved (see supplementary data online, Videos S4 and S5). He was discharged on apixaban without symptoms of post-thrombotic syndrome (Panel F).

19 December 2025 in JACC: Asia
Verified
Journal Article
Open access
MSMadoka Sano
Madoka Sano
TTToshiaki Toyota
Toshiaki Toyota
YMYoshinori Matsuoka
Yoshinori Matsuoka
HKHirohiko Kohjitani
Hirohiko Kohjitani
YWYusuke Watanabe
Yusuke Watanabe
YFYutaka Furukawa
Yutaka Furukawa
Extracorporeal cardiopulmonary resuscitation (ECPR), an emerging resuscitative therapy following refractory cardiac arrests, is associated with hemorrhagic complications that potentially affect patient outcomes. This study evaluated the risks and predictors of hemorrhagic complications among patients who underwent ECPR for out-of-hospital cardiac arrest (OHCA) from different causes. Using the SAVE-J II (Study of Advanced Cardiac Life Support for Ventricular Fibrillation with Extracorporeal Circulation in Japan) study, we analyzed multicentric data of patients who underwent ECPR for OHCA from 2013 to 2018 in Japan. Based on the causes of OHCA, the participants were stratified into endogenous cardiac, endogenous noncardiac, and exogenous groups. The primary outcome was any bleeding. Among 1,935 patients, 1,417, 305, and 213 patients had endogenous cardiac, endogenous noncardiac, and exogenous causes, respectively. For survivors, the median follow-up period was 36 days, and most of the bleeding events occurred within 1 week post-ECPR. The 30-day cumulative incidence of any bleeding significantly differed among the 3 groups (endogenous cardiac: n = 321 [25.9%]; endogenous noncardiac: n = 41 [18.9%]; and exogenous: n = 27 [13.7%]; P < 0.001). However, the risks for bleeding complications did not differ between the causes of OHCA after adjustment for confounders. Intra-aortic balloon pumping use was associated with higher risks of bleedings and lower risk for all-cause death. Underlying causes of OHCA did not significantly impact adjusted bleeding risks. Intra-aortic balloon pumping use was independently associated with higher bleeding risks and lower mortality, although this warrants cautious interpretation because of a potential selection bias. Vigilant monitoring for bleeding complications is crucial in ECPR patients, especially in those with additional circulatory support devices.